Nucleophosmin (NPM1) mutations occur frequently in adult cytogenetically normal acute myeloid leukemia (CN-AML) and confer favorable outcome. We investigated the frequency and prognostic significance of NPM1 mutations in childhood AML (n ¼ 298), specifically focusing on the CN-AML subgroup (n ¼ 100). Mutations were found in 8.4%, and clustered significantly in the CN-AML subgroup (22%). No mutations were found in patients below the age of 3 years; in CN-AML, there was an increasing incidence above this age. In the overall group, NPM1 mutations conferred an independent favorable prognostic impact on event-free survival (5-year pEFS 66 vs 39%; P ¼ 0.02), which did not translate into a significantly better overall survival (5-year pOS 68 vs 56%; P ¼ 0.30). However, when the favorable cytogenetic subgroups [inv(16) and t(8;21)] were excluded from the NPM1 wild-type group, the difference in pOS was borderline statistically significant (68 vs 45%; P ¼ 0.07). In the CN-AML cohort, NPM1 mutations were an independent prognostic factor on pEFS (80 vs 39%; P ¼ 0.01), and pOS (85 vs 60%; P ¼ 0.06), which was not influenced by FLT3/ITD. However, in NPM1 wild-type CN-AML, FLT3/ITDpositive patients had a significantly worse outcome (pEFS 48 vs 18%; Po0.001). We conclude that NPM1 mutations confer a favorable prognosis in childhood AML and in CN-AML in particular.
Introduction
Nucleophosmin (NPM1), encoded by the NPM1 gene localized at chromosome 5q35, is a multifunctional nucleo-cytoplasmic shuttling protein that is predominantly localized in the nucleoli. The protein functions in different cellular processes, such as ribosome biogenesis, centrosomal duplication, maintenance of genomic integrity and the ARF-p53 tumor-suppressor pathway. [1] [2] [3] [4] NPM1 mutations, which occur in exon 12, encoding for the C terminus of the NPM1 protein, have recently been described in adult acute myeloid leukemia (AML). 5 They consist of net insertions of four nucleotides, affecting at least one of the tryptophan residues at amino acid positions 288 or 290. Loss of these tryptophan residues, as well as the creation of an additional nuclear export signal motif, causes delocalization of the protein to the cytoplasm. 6, 7 This aberrant cytoplasmic localization of the NPM1 protein can easily be detected by immunocytochemistry. 5 Nucleophosmin mutations are present in approximately 50-60% of adult cytogenetically normal AML (CN-AML) samples, 5, [8] [9] [10] [11] [12] [13] [14] among several other newly identified molecular abnormalities. 15 They confer a favorable clinical outcome in this subgroup of patients. 8, 12, 14 However, this favorable prognosis is lost in patients whose AML cells harbor both a mutation in NPM1 as well as an internal tandem duplication in the FLT3 gene (FLT3/ITD). 8, 9, 12, 14 Cytogenetically normal-AML is less frequent in children than in adults, and accounts for ±20 to 25% of childhood AML cases. 16 This CN-AML subgroup lacks favorable prognostic cytogenetic aberrations, leading to stratification in the intermediate or high-risk arm of risk-adapted pediatric AML treatment protocols. Recent studies from the Childhood Oncology Group (COG), reporting results from the POG-9421 protocol, and from the AIEOP (Associazione Italliana di Ematologica e Oncologica Pediatrica) on their AML02 protocol, showed NPM1 mutations in 6.5 to 8% of childhood AML cases. 17, 18 However, in studies from the Japanese Childhood AML Cooperative Study Group and a Taiwanese study, lower frequencies of 0 to 2.1% were found. 10, 19 NPM1 mutations in children also cluster in the CN-AML subgroup, but the frequencies described range from 0% to 27%. 10, [17] [18] [19] [20] To date, only the COG analyzed the prognostic significance of NPM1 mutations in childhood AML, showing favorable outcome for children with NPM1-mutated AML lacking a FLT3 mutation. 18 However, this report does not focus on the CN-AML subgroup.
We therefore screened 298 childhood AML samples to determine the overall frequency of NPM1 mutations. Besides a survival analysis in the total cohort of de novo childhood AML patients, we performed a subgroup analysis on CN-AML patients to analyze the prognostic significance of NPM1 mutations in this subgroup specifically. NPM1 mutations were found to confer an independent favorable probability of event-free survival (pEFS), but not significantly better probability of overall survival (pOS), in childhood AML overall. However, in childhood CN-AML, NPM1 mutations were found to confer an independent favorable prognostic impact for both parameters.
Materials and methods

Patient samples
Viably frozen bone marrow or peripheral blood samples from children with AML were provided by the Dutch Childhood Oncology Group (DCOG, The Hague, The Netherlands) and the AML-Berlin-Frankfurt-Mü nster Study Group (AML-BFM SG, Hannover, Germany). The Institutional ethical review board approval for these studies had been obtained according to local law and regulations. Each study group performed a central review of the morphological and cytogenetic classification, as well as a clinical follow-up of these patients.
Leukemic samples were routinely investigated for cytogenetic abnormalities by standard chromosome-banding analysis, and screened for recurrent nonrandom genetic abnormalities characteristic for AML, including t(15;17), inv(16), t(8;21) and MLL gene rearrangements, using either reverse transcription-PCR and/or fluorescent in situ hybridization.
After thawing, contaminating non-leukemic cells were removed using immunomagnetic beads as described earlier. 21 Blast percentages were assessed morphologically on MayGrü nwald-Giemsa-stained cytospin slides.
Mutational screening data from a part (n ¼ 75) of the patients have been reported earlier elsewhere. 20 
Treatment protocols
Patients were treated according to subsequent German and Dutch childhood AML treatment protocols between 1982 and 2005. The survival analysis was, however, restricted to the de novo AML patients treated according to the following consecutive protocols (AML-BFM/DCOG 87, AML-BFM/DCOG 93/ 92-94, DCOG 97, AML-BFM 98 and AML-BFM 04), to reduce variability in treatment regimens, and because this comprised the majority of patients (n ¼ 264, see results section). Details of these treatment protocols and overall outcome data have been published earlier, with the exception of study AML-BFM 04, which is ongoing. [22] [23] [24] In these protocols, treatment consisted of four to five blocks of intensive chemotherapy, using a standard cytarabine and anthracycline backbone. Stem cell transplantation (SCT) in first complete remission (CR1) was used only in selected high-risk patients.
Mutational analysis of NPM1 and FLT3/ITD
Mutational analysis of NPM1 and FLT3/ITD was performed both in Rotterdam and in Dresden. As a quality control, 20 samples, enriched for CN-AML samples, were assessed blinded in both laboratories. No discrepancies in results were found.
Genomic DNA was extracted from the leukemic cells using TRIzol reagent (Invitrogen Life Technologies, Breda, the Netherlands) or Qiagen Blood DNA kits (Qiagen, Hilden, Germany), according to the manufacturer's instructions. 25 In Rotterdam, exon 12 of the NPM1 gene was PCR amplified using the following primers NPM1-F: 5 0 CTG GTG GTA GAA TGA AAA ATA GAT3 0 and NPM1-R: 5 0 GGC AGG GAC ATT CTC ATA G3, situated in intron 11 and 3 0 -UTR, respectively. Purified PCR products were directly sequenced using the described reverse primer. NPM1 mutants without an unambiguously identified sequence were confirmed by cloning using the TOPO-TA cloning kit (Invitrogen Life Technologies), followed by direct sequencing. In Dresden, samples were analyzed with PCR amplification followed by GeneScan analysis, as reported earlier. 8 Sequencing was performed for confirmation when a mutation was identified. Detection of FLT3/ITD was performed on genomic DNA by PCR amplification followed by GeneScan analysis or by gel electrophoresis and additional GeneScan analysis in case of a positive FLT3/ITD.
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Statistical analysis
To compare categorical variables we used w 2 analysis and Fisher's exact test in case of small numbers. The nonparametric Mann-Whitney U-test was applied for continuous variables.
To assess outcome, the following parameters were used: CR rate, pEFS (defined as time between diagnosis and first event, including relapse, death of any cause, failure to achieve remission or second malignancy), pOS (defined as time between diagnosis and death from any cause), and the cumulative incidence of relapses (defined as the time between time of diagnosis and relapse). pEFS and pOS were estimated by the Kaplan-Meier method, and compared using the log-rank test. The cumulative incidence of relapse curves were constructed by the method of Kalbfleisch and Prentice, and were compared using Gray's test. Prognostic factors were examined by multivariate Cox regression analysis.
P-values of p0.05 were considered statistically significant (two-tailed testing).
Results
Study population
Of the 298 newly diagnosed AML samples whose cells were available to us, we successfully screened 297 samples for NPM1 mutations. One sample failed because of unsuccessful harvesting of DNA. The successfully screened cohort included 286 patients with de novo, 10 with secondary and 1 with Down's syndrome AML. Patient characteristics are shown in Table 1 . Survival analysis was restricted to patients with de novo AML, and in addition the following patients were excluded: patients treated according to other protocols (n ¼ 7), patients lost to follow-up (n ¼ 3), treatment without curative intent (n ¼ 1), isolated myelosarcoma (n ¼ 3) and PML-RARa (n ¼ 8). We compared the characteristics of this cohort (n ¼ 264) with the other not-investigated patients who were treated according to the same study protocols and after excluding the same subgroups (n ¼ 871). There were no significant differences in French-American-British (FAB) subtypes or karyotype distribution between these two groups. However, in our study cohort, there were significantly less females (40 vs 50%; P ¼ 0.007), and less children below 2 years of age (19 vs 37%; Po0.001), but they had higher white blood cell counts at diagnosis (WBC) (WBC o20 Â 10 9 /l: 34 vs 61%; Po0.001). The cohort used for survival analysis included 63 samples of patients with CN-AML. Subsequently, we identified another 37 de novo CN-AML samples from patients treated on the same therapy protocols from various cell banks. Patient characteristics of these 100 CN-AML samples are shown in Table 2 . This cohort was used to further describe the prognostic impact of NPM1 mutations in the subgroup of CN-AML.
We also successfully tested 46 paired diagnosis-relapse samples.
Type of NPM1 mutations
All detected NPM1 mutations consisted of net insertions of four nucleotides, resulting in a shift of the reading frame with loss of at least one of the two tryptophans, and the creation of a nuclear export signal (Table 3 ). The predominant type of mutation was a CATG insertion (type B, 40%), followed by a TCTG insertion (type A) in 20% of samples. Two novel mutations were identified, consisting of an insertion of 10 plus a deletion of 6 nucleotides, and an insertion of 12 plus deletion of 8 nucleotides in one single patient each, both affecting only the tryptophan residue 290.
NPM1 mutations in the genetic subgroups
Overall, NPM1 mutations were identified in 8.4% (25 of 297) of childhood AML samples. No mutations were detected in patients with secondary or Down's syndrome AML.
NPM1 mutations were not randomly distributed over the different cytogenetic subgroups within AML (Figure 1 ), but showed a significant clustering in the CN-AML cases (15 of 67 (22.4%)) compared with cases with cytogenetic aberrations (5 of 201 (2.5%); Po0.001). No mutations were found either in the favorable karyotype subgroups t(8;21), inv (16) or t (15;17) or in the MLL gene-rearranged AML cases. However, within the complex karyotype subgroup, 1 of 12 (8.3%) samples was mutated, as were 4 of 58 samples (6.9%) in the group with 'other cytogenetic abnormalities.' These five cases with NPM1 mutations and cytogenetic abnormalities carried the following Table 1 Clinical characteristics of the 297 successfully screened pediatric AML patients, divided by NPM1 mutational status 
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an add(4)(p); patient (4) a del(9)(q) and patient (5) a t(7;12)(p12;p13). Of 29 samples, karyotypic information was lacking, and five of these samples (17.2%) appeared to be mutated. Of these 29 cases, we were able to screen 20 samples for nonrandom abnormalities such as core-binding factor abnormalities and MLL gene rearrangements using molecular methods such as fluorescent in situ hybridization or PCR. These nonrandom abnormalities were not found in this subgroup.
There was an increased frequency of FLT3/ITD positivity in NPM1-mutated AML (40%) compared with NPM1 wild-type AML (17%; P ¼ 0.006) ( Table 1 ). However, no significant differences were seen between the two groups regarding the FLT3/ITD characteristics, such as the allelic ratio (AR) or the ITD length. There was no correlation between the type of NPM1 mutation and FLT3/ITD positivity.
Paired diagnostic-relapse samples
The 46 tested diagnosis-relapse pairs included three cases with mutated NPM1 and 43 cases with wild-type NPM1. The three NPM1-mutated cases carried the same mutation at relapse, and none of the 43 NPM1 wild-type cases gained a mutation at relapse; so no clonal instability of NPM1 mutations was observed in this set of patients.
Relationship between NPM1 mutations and clinical characteristics NPM1 mutations were not found below the age of 3 years, but showed a steady frequency of 10-11% in children aged 3 years and above (Table 1) . However, analysis restricted to the CN-AML subgroup showed a trend for an increasing frequency above the age of 3 years: 0% below the age of 3 years; 21% in the age group 3 years or older but below 10 years, and 27% in children aged 10 years or older (P ¼ 0.06) ( Table 2 ). There was no clear correlation between the type of mutation and age.
There was no difference in WBC between NPM1-mutated (median 39.3 Â 10 9 /l) and NPM1 wild-type AML samples (median 37.7 Â 10 9 /l; P ¼ 0.89). NPM1-mutated AML patients were more likely to be female (64%) compared with wild-type patients (41%; P ¼ 0.03). The FAB subtypes were not equally distributed between the two groups (P ¼ 0.02). This difference was mainly because of the absence of the FAB M5-subtype in the NPM1-mutated cases (0 of 25 vs 69 of 272; P ¼ 0.004). This absence of the FAB M5-subtype in NPM1-mutated AML was also seen in the CN-AML subgroup.
Prognostic impact of NPM1 mutations in childhood AML
The median follow-up time for survivors was 36.5 months (38.7 months for NPM1-mutated and 36.2 months for wild-type patients; P ¼ 0.76). There were no significant differences in the pEFS between the various protocols (P ¼ 0.58). The frequency of SCT in CR1 was 15.2%, and it did not differ significantly Table 3 Distribution of the types of NPM1 gene mutations, the DNA-sequence and predicted protein, as identified in this study, categorized according to Falini et NPM1-mutated AML patients had an excellent CR rate (92.0%). None of them was refractory to induction therapy, but two patients were lost because of an early death. The CR rate did not differ significantly from the wild-type cases (84.5%; P ¼ 0.31). NPM1-mutated AML patients had a significantly better 5-year pEFS (66±10%) compared with wild-type patients (39 ± 4%; P ¼ 0.02) (Figure 2a) . However, this did not translate into a better 5-year pOS (68±10% vs 56±4%, respectively; P ¼ 0.30) (Figure 2b) . However, when excluding the favorable prognostic subgroup (defined as AML with inv(16) or t(8;21)) from the NPM1 wild-type group, NPM1-mutated AML patients had a better 5-year pOS (68±10% vs 45±4%) that was borderline significant (P ¼ 0.07 or P ¼ 0.03 when the difference was tested as point estimate at 5 years).
FLT3/ITD was a significantly prognostic factor for pEFS as well as for pOS (FLT3/ITD-positive case vs FLT3/ITD-negative case: 5-year pEFS 25 ± 9 vs 44 ± 4%; P ¼ 0.05 and 5-year pOS 42 ± 8 vs 63 ± 4%, respectively; P ¼ 0.04). When analyzing outcome according to the combined NPM1 and FLT3/ITD status, we did not find a negative influence on the outcome of FLT3/ITD in the NPM1-mutated patients (FLT3/ITD-positive case vs FLT3/ ITD-negative case, 5-year pEFS 79 ± 13 vs 58 ± 13%; P ¼ 0.29, and 5-year pOS 74±16 vs 64±13%, respectively; P ¼ 0.44) (Figures 2c and d) . However, FLT3/ITD was a significantly poor prognostic factor for the NPM1 wild-type AML patients (FLT3/ ITD-positive case vs FLT3/ITD-negative case, 5-year pEFS 11 ± 9 vs 43±4%; Po0.001, and 5-year pOS 33±9 vs 63±4%, respectively; P ¼ 0.004).
No significant differences in effect on outcome were found between the different types of NPM1 mutations (data not shown); however, the numbers were small.
Prognostic impact in the subgroup of CN-AML
The median follow-up time for survivors was 60.1 months. There were no significant differences in pEFS between the various protocols (P ¼ 0.59). The frequency of SCT in CR1 in CN-AML was 22% and did not differ significantly either between NPM1-mutated (25%) and wild-type patients (21%; P ¼ 0.77) or between FLT3/ITD-positive (26%) and -negative patients (20%; P ¼ 0.51).
The CR rate for the 20 NPM1-mutated AML patients was 95.0%; one patient was lost because of cerebral bleeding. In the 80 wild-type patients, the CR rate was 82.5%; 4 patients died early because of complications, and 10 patients were refractory to induction therapy. However, this difference in CR rate did not reach statistical significance (P ¼ 0.29). NPM1-mutated AML patients had a significantly better 5-year pEFS (80±9%) than the wild-type patients (40 ± 6%) (P ¼ 0.02; Figure 3a) . The 5-year pOS for NPM1-mutated compared with wild-type patients was 85 ± 8 vs 59 ± 6%, respectively (Figure 3b) , which was border- Prognosis of NPM1 mutations in childhood CN-AML IHIM Hollink et al line statistically significant (P ¼ 0.06). When we tested the difference in survival as a point estimate at 5 years, the difference was statistically significant (P ¼ 0.01). The 5-year cumulative incidence of relapse was 15 ± 8% for the NPM1-mutated vs 39 ± 8% for the wild-type patients (p(Gray) ¼ 0.18). It is interesting to note that survival analysis was influenced by one late event in the NPM1-mutated group. This concerned a late relapse that occurred 8 years after initial diagnosis, without a change in FAB type, immunophenotype or karyotype between the diagnosis and relapse sample. The median time to relapse from CR1 was 14.2 months in the four relapsed NPM1-mutated cases. FLT3/ITD-positive AML patients had a 5-year pEFS of 38 ± 9 vs 52 ± 7% in patients without FLT3/ITD (P ¼ 0.10). The 5-year pOS was 54 ± 9 vs 70 ± 6%, respectively (P ¼ 0.08). Despite the relatively small numbers, we next analyzed the effect that FLT3/ ITD had on outcome within the NPM1-mutated and NPM1 wild-type subgroups separately (Figures 3c and d (n ¼ 10), in terms of 5-year pEFS (90 ± 9 vs 70 ± 14%; P ¼ 0.62) and pOS (90±9 vs 80±13%; P ¼ 0.54). Within the NPM1 wild-type subgroup, FLT3/ITD-positive (n ¼ 25) patients had a significantly worse outcome than did FLT3/ITD-negative patients (n ¼ 55) in terms of 5-year pEFS (18 ± 10 vs 48 ± 7%; P ¼ 0.006) and pOS (40±11 vs 68±7%; P ¼ 0.009). As we did not identify a difference in outcome based on FLT3/ITD within the NPM1-mutated group, we also subdivided the patients into three rather than four subgroups (Figures 3e and f) , that is, NPM1-mutated AML, irrespective of FLT3/ITD status (5-year pEFS 80 ± 9%); NPM1 wild-type and FLT3/ITD-negative AML (5-year pEFS 48±7%) and NPM1 wild-type AML harboring an FLT3/ITD as a single abnormality (5-year pEFS 18 ± 10%; Po0.001). The effect of FLT3/ITD did not change when analyses were performed with FLT3/ITD AR or ITD length instead of the presence of FLT3/ITD per se.
Multivariate analysis of prognostic factors
When we included NPM1 mutations with other risk factors in the Cox model, including age (utilizing 10 years of age as the cutoff value), WBC (using 50 Â 10 9 /l as the cutoff value), FLT3/ ITD and SCT as time-dependent co-variables, we identified NPM1 mutations as an independent factor for pEFS (risk ratio (RR) 0.38; 95% confidence interval (CI) 0.18-0.80; P ¼ 0.01), but not for pOS (RR 0.66 (0.30-1.47); P ¼ 0.31) ( Table 4) .
In CN-AML, an NPM1 mutation was the strongest independent predicting risk factor for pEFS (RR 0.29; 95% CI 0.11-0.75; P ¼ 0.01) as well as for pOS (RR 0.30; 95% CI 0.09-1.00; P ¼ 0.05) ( Table 3) . FLT3/ITD did not reach significance in the model either for pEFS or for pOS (Table 4) . When we entered FLT3/ITD with high ARs (X0.4) in the model instead of FLT3/ ITD per se, this did not change the results.
Discussion
Our study confirms the observed lower frequency (7-9%) of NPM1 mutations in childhood AML, compared with adult AML (25-35%), as reported earlier by the COG (POG-9421 study) and the AEIOP-AML02 study. 17, 18, 28 In agreement with studies on adult AML, NPM1 mutations were mainly observed in the cytogenetically normal subgroup (CN-AML) (22%). However, this frequency is significantly lower than the observed frequency in adult CN-AML (50-60%). Very low frequencies of NPM1 mutations (0.0-2.1%) were found in Asian children with CN-AML, 10, 19 although similar age cohorts were studied. This may be because of the ethnic differences in genetic subgroup distribution as has also been suggested for acute promyelocytic leukemia and PTPN-11 mutations. 29, 30 Interestingly, no mutations were found in children below the age of 3 years. Moreover, this frequency appeared to be agerelated in the CN-AML subgroup, with an increasing frequency from the age of 3 years onward. A similar tendency has been described for FLT3/ITD mutations. 31 These data suggest that there may be differences in leukemogenesis between CN-AML in very young (o3 years of age) and older pediatric AML patients. As FAB M5 is the predominant FAB subtype in very young children with AML, 32 which are usually characterized by MLL rearrangements, this also explains in part our finding of the absence of NPM1 mutations in AML FAB M5. In another pediatric study also, none out of the 18 tested FAB M5 cases harbored an NPM1 mutation. 17 This is in contrast with adult studies where NPM1 mutations are predominantly found in myelomonoblastic leukemias (FAB M4 and M5).
In adult AML, several studies have shown the favorable impact of NPM1 mutations on prognosis, but there is a paucity of published data on childhood AML, in particular on CN-AML cases. Only the COG reported a favorable outcome for children with NPM1-mutated AML lacking FLT3/ITD, 18 and they presented a trend toward improved survival for children with NPM1-mutated CN-AML (pOS 56 vs 39%, P ¼ 0.15). 33 In our study on de novo childhood AML patients, we showed an independent favorable outcome for children with NPM1-mutated AML in terms of pEFS; however, this did not translate into a significantly better pOS. This was mainly because of the high salvage rate of patients without NPM1 mutations after relapse. 34 When analyzing this further, it appeared that the high salvage rate was mainly because of patients with favorable-risk AML carrying either a t(8;21) or inv(16) (acute promyelocytic leukemia cases were already excluded from the analysis), but without NPM1 mutations. When they were excluded from the comparison, the difference in pOS between NPM1-mutated and NPM1 wild-type cases was borderline statistically significant. We therefore feel it is justified to conclude that NPM1 does confer a favorable outcome in pediatric AML, as also shown by the pediatric study of Brown et al. 18 Our data also suggest that in future prospective studies the analysis of NPM1 mutations should not be restricted to the CN-AML subgroup only, but should also be performed in all patients.
When focusing on the CN-AML subgroup, which is the largest pediatric CN-AML cohort studied to date, we detected NPM1 mutations in B20% of the cases. Patients with NPM1-mutated CN-AML experienced an excellent outcome with 85% survival, and the presence of an NPM1 mutation was found to be an independent predictor of prognosis in multivariate analysis. The Table 4 Results of multivariate analysis for pEFS and pOS in childhood AML and the subgroup of CN-AML /l; age 410 indicates age with cutoff value above 10 years old; FLT3/ITD, internal tandem duplication of the FLT3 gene; pEFS, probability of event-free survival; pOS, probability of overall survival and SCT indicates stem cell transplantation. In the overall group of childhood acute myeloid leukemia patients, patients with favorable cytogenetics (defined as t(8;21) or inv(16)) were not excluded (see text results section).
outcome data presented here are significantly better than those reported in other series of NPM1-mutated CN-AML, as the outcome is usually in the 30-50% range in adults, and survival reached 56% in the pediatric POG-9421 study, which suggests that the clinical outcome of NPM1-mutated patients may be treatment-dependent. 8, 9, [12] [13] [14] 33 FLT3/ITD had no significant effect on outcome in the NPM1-mutated group in our study. This is different from the findings in most adult studies on CN-AML, as well as the results from the pediatric POG-9421 study, which reported that FLT3/ITD overrules the favorable effect of NPM1 mutations. 8, 9, 12, 14, 18 However, it needs to be kept in mind that our data were based on 20 CN-AML patients with NPM1 mutations only, and hence confirmation in a larger series is needed. It is interesting to note that , a recent large study of the Medical Research Council in adult CN-AML also reported a positive effect of NPM1 mutations in the FLT3/ITD-positive group, irrespective of the FLT3/ITD AR. 35 We did not identify differences in the characteristics of FLT3/ITD, that is, AR or ITD length, that could explain why FLT3/ITD did not have a prognostic influence in our NPM1-mutated patients. In addition, SCT could not explain the difference in impact; only a small number of our patients were transplanted, and there were no significant differences in the number of patients transplanted in the various subgroups. Moreover, SCT did not have independent prognostic significance in the Cox model. No significant differences in outcome were detected between the different types of NPM1 mutations, although the numbers were small. There are currently no data available from adult studies suggesting differences in outcome between type A (which is found in B80% of adult AML compared with only 20% in our cohort) and the other mutations. Hence, it remains speculative whether the excellent outcome data in NPM1-mutated childhood (CN-)AML presented here may be because of differences in the underlying biology of the various NPM1 mutations.
Our study also has important implications for pediatric (CN)-AML patients with wild-type NPM1, as the presence or absence of FLT3/ITD clearly distinguished between two subgroups: one characterized by FLT3/ITD and a poor prognosis, and one characterized by wild-type FLT3 and an intermediate prognosis.
In multivariate analysis restricted to the NPM1 wild-type CN-AML patients, FLT3/ITD was confirmed as the strongest predictor for pEFS (data not shown).
Recently, Mrozek et al. 15 suggested that molecular dissection of adult CN-AML may be relevant for treatment stratification in clinical practice, and they proposed an algorithm related to the molecular abnormalities identified in this subgroup. In this algorithm, patients with FLT3/ITD have poor outcome, irrespective of NPM1 status. On the basis of our data, the clinical consequences of NPM1 mutations and FLT3/ITD may differ between children and adults, and therefore the implementation of this algorithm for children may not be warranted until more pediatric data become available. The first step would be to prospectively validate our results in a larger uniformly treated patient group. This is needed to avoid the potential selection bias and heterogeneity of treatment, which are the obvious drawbacks of a retrospective study. Another potential limitation of our study was that patients were treated on different therapy protocols, although all protocols used the same backbone of cytarabine and anthracycline, and consisted of 4-5 blocks of intensive chemotherapy. Moreover, there was no significant influence on prognosis between the different protocols.
When comparing NPM1 mutations in the initial diagnosisrelapse pairs, no discrepancies were found. In particular, in the 43 samples with wild-type NPM1 at initial diagnosis, no other NPM1 mutations were identified at relapse, suggesting that NPM1 mutations may be important as early events in AML. We did not identify any NPM1 mutation losses at relapse, different from what has been found in AML with FLT3/ITD. 26 However, only three NPM1-mutated diagnosis-relapse pairs could be investigated. This stability may be relevant when using NPM1 mutations as a marker for MRD studies.
Taken together, our data suggest that NPM1-mutated AML, in particular within the subgroup of CN-AML, should be classified as a separate and distinct entity in pediatric AML. Moreover, in patients with NPM1 wild-type (CN-)AML, FLT3/ITD distinguishes between patients with an intermediate and a poor clinical outcome. These data may have important consequences for stratification of AML patients, and particularly patients with CN-AML in future pediatric AML treatment protocols, when they can be prospectively validated.
